PATHOPHYSIOLOGICAL MECHANISMS LINKING CHRONIC STRESS TO ALTERED DRUG RESPONSE: A NARRATIVE REVIEW OF PHARMACOKINETIC AND PHARMACODYNAMIC CONSEQUENCES
PDF
HTML

Keywords

chronic stress
pharmacokinetics
pharmacodynamics
cytochrome P450
inflammation
gastrointestinal microbiome
epigenomics
pharmacovigilance

How to Cite

Cordero, G. A., Khaitovych, M. V., Udovytskyi, V. V., Rogozin, V. V., & Usenko, V. O. (2026). PATHOPHYSIOLOGICAL MECHANISMS LINKING CHRONIC STRESS TO ALTERED DRUG RESPONSE: A NARRATIVE REVIEW OF PHARMACOKINETIC AND PHARMACODYNAMIC CONSEQUENCES. Clinical and Preventive Medicine, (7), 170-181. https://doi.org/10.31612/2616-4868.7.2026.20

Abstract

Introduction. Interindividual variability in drug response is conventionally attributed to genetic polymorphism, age, sex, organ function, comorbidity, adherence, diet and drug–drug interactions. This framework tacitly assumes that the physiological environment of pharmacotherapy is stable. Sustained psychological stress violates that assumption.

Aim. To synthesise the mechanistic and clinical evidence on how chronic stress alters drug disposition and response, to compare the strength of that evidence across mechanisms, and to define what may reasonably be translated into clinical practice.

Materials and methods. Narrative, mechanism-oriented synthesis of peer-reviewed literature identified in PubMed and Scopus for the period 2004–2026, across neuroendocrinology, immunology, gastroenterology, clinical pharmacology and psychiatry. Each mechanism was appraised against predefined criteria: level of evidence, direction and magnitude of effect, and translational readiness.

Results. Sustained activation of the hypothalamic–pituitary–adrenal axis and of the sympathetic–adrenomedullary system reshapes cytochrome P450 activity in an isoform-specific manner, sustains low-grade inflammation capable of shifting the metabolic phenotype independently of genotype, increases intestinal permeability, modifies microbial biotransformation and efflux transport at the intestinal wall and the blood–brain barrier, and drives receptor desensitisation. The direction of change is not uniform, so the clinical presentation is context-dependent: reduced efficacy, increased toxicity, delayed response, or unstable variability. Effect magnitude differs across mechanisms by about an order of magnitude.

Conclusions. Chronic stress is best conceptualised as a dynamic component of the individual exposome rather than as a behavioural confounder. The defensible clinical position is intensified monitoring and careful interpretation of apparent treatment failure, not dose adjustment on the mere presence of stress.

https://doi.org/10.31612/2616-4868.7.2026.20
PDF
HTML

References

Abbas, K., Habib, S., Mustafa, M., Alam, M., & Usmani, N. (2026). Epigenetics of chronic stress: mechanisms and health impacts. Curr Genomics. https://doi.org/10.2174/0113892029402870251108055234

Bauer, B., Hartz, A. M., & Miller, D. S. (2007). Tumor necrosis factor α and endothelin-1 increase P-glycoprotein expression and transport activity at the blood–brain barrier. Mol Pharmacol, 71(3), 667–675. https://doi.org/10.1124/mol.106.030528

Chrousos, G. P. (2009). Stress and disorders of the stress system. Nat Rev Endocrinol, 5(7), 374–381. https://doi.org/10.1038/nrendo.2009.106

Cohen, S., Janicki-Deverts, D., Doyle, W. J., Miller, G. E., Frank, E., Rabin, B. S., et al. (2012). Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci U S A, 109(16), 5995–5999. https://doi.org/10.1073/pnas.1118355109

Colloca, L., & Barsky, A. J. (2020). Placebo and nocebo effects. N Engl J Med, 382(6), 554–561. https://doi.org/10.1056/NEJMra1907805

Darwich, A. S., Ogungbenro, K., Vinks, A. A., Powell, J. R., Reny, J. L., Marsousi, N., et al. (2017). Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. Clin Pharmacol Ther, 101(5), 646–656. https://doi.org/10.1002/cpt.659

de Jong, L. M., Jiskoot, W., Swen, J. J., & Manson, M. L. (2020). Distinct effects of inflammation on cytochrome P450 regulation and drug metabolism: lessons from experimental models and a potential role for pharmacogenetics. Genes (Basel), 11(12), 1509. https://doi.org/10.3390/genes11121509

Dion, A., Torres Muñoz, P., & Franklin, T. B. (2022). Epigenetic mechanisms impacted by chronic stress across the rodent lifespan. Neurobiol Stress, 17, 100434. https://doi.org/10.1016/j.ynstr.2022.100434

Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016). Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med, 22(3), 238–249. https://doi.org/10.1038/nm.4050

Haduch, A., Bromek, E., Rysz, M., Pukło, R., Papp, M., Gruca, P., et al. (2020). The effects of agomelatine and imipramine on liver cytochrome P450 during chronic mild stress in the rat. Pharmacol Rep, 72(5), 1271–1287. https://doi.org/10.1007/s43440-020-00130-9

Haduch, A., Bromek, E., Wojcikowski, J., Golembiowska, K., & Daniel, W. A. (2018). The activity of brain and liver cytochrome P450 2D is differently affected by antidepressants in the chronic mild stress model of depression in the rat. Biochem Pharmacol, 156, 398–408. https://doi.org/10.1016/j.bcp.2018.09.006

Hartmann, J., Bajaj, T., Klengel, C., Chatzinakos, C., Ebert, T., Dedic, N., et al. (2021). Mineralocorticoid receptors dampen glucocorticoid receptor sensitivity to stress via regulation of FKBP5. Cell Rep, 35(9), 109185. https://doi.org/10.1016/j.celrep.2021.109185

Jiang, X., Zhang, Z., Li, Y., Wang, Y., & Chen, X. (2022). Effect of chronic unpredicted mild stress-induced depression on clopidogrel pharmacokinetics in rats. PeerJ, 10, e14111. https://doi.org/10.7717/peerj.14111

Jürgens, M., Claus, M., Wingert, S., Niemann, J. A., Picard, L. K., Hennes, E., et al. (2024). Chronic stimulation desensitizes β2-adrenergic receptor responses in natural killer cells. Eur J Immunol, 54(12), e2451299. https://doi.org/10.1002/eji.202451299

Kirchheiner, J., & Seeringer, A. (2007). Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta, 1770(3), 489–494. https://doi.org/10.1016/j.bbagen.2006.09.018

Klomp, S. D., Manson, M. L., Guchelaar, H. J., & Swen, J. J. (2020). Phenoconversion of cytochrome P450 metabolism: a systematic review. J Clin Med, 9(9), 2890. https://doi.org/10.3390/jcm9092890

Konstandi, M., Johnson, E. O., & Lang, M. A. (2022). Stress as a potential regulatory factor in the outcome of pharmacotherapy. Front Neurosci, 16, 737716. https://doi.org/10.3389/fnins.2022.737716

Kot, M., Haduch, A., Papp, M., & Daniel, W. A. (2017). The effect of chronic treatment with lurasidone on rat liver cytochrome P450 expression and activity in the chronic mild stress model of depression. Drug Metab Dispos, 45(12), 1336–1344. https://doi.org/10.1124/dmd.117.077271

Lenoir, C., Rollason, V., Desmeules, J. A., & Samer, C. F. (2021). Influence of inflammation on cytochromes P450 activity in adults: a systematic review of the literature. Front Pharmacol, 12, 733935. https://doi.org/10.3389/fphar.2021.733935

Malekpour, M., Shekouh, D., Safavinia, M. E., Shiralipour, S., Jalouli, M., Mortezanejad, S., et al. (2023). Role of FKBP5 and its genetic mutations in stress-induced psychiatric disorders: an opportunity for drug discovery. Front Psychiatry, 14, 1182345. https://doi.org/10.3389/fpsyt.2023.1182345

Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol, 2(6), 875–894. https://doi.org/10.1517/17425255.2.6.875

Matosin, N., Cruceanu, C., & Binder, E. B. (2017). Preclinical and clinical evidence of DNA methylation changes in response to trauma and chronic stress. Chronic Stress (Thousand Oaks), 1, 2470547017710764. https://doi.org/10.1177/2470547017710764

McEwen, B. S. (1998). Protective and damaging effects of stress mediators. N Engl J Med, 338(3), 171–179. https://doi.org/10.1056/NEJM199801153380307

McEwen, B. S., & Stellar, E. (1993). Stress and the individual: mechanisms leading to disease. Arch Intern Med, 153(18), 2093–2101. https://doi.org/10.1001/archinte.1993.00410180039004

Miller, D. S. (2015). Regulation of ABC transporters at the blood–brain barrier. Clin Pharmacol Ther, 97(4), 395–403. https://doi.org/10.1002/cpt.47

Miller, G. E., Chen, E., & Zhou, E. S. (2007). If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans. Psychol Bull, 133(1), 25–45. https://doi.org/10.1037/0033-2909.133.1.25

Morgan, E. T. (2009). Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther, 85(4), 434–438. https://doi.org/10.1038/clpt.2008.302

Murphy, M. D., & Heller, E. A. (2022). Convergent actions of stress and stimulants via epigenetic regulation of neural circuitry. Trends Neurosci, 45(12), 955–967. https://doi.org/10.1016/j.tins.2022.10.001

Nelson, D. R., Zeldin, D. C., Hoffman, S. M. G., Maltais, L. J., Wain, H. M., & Nebert, D. W. (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics, 14(1), 1–18. https://doi.org/10.1097/00008571-200401000-00001

Okumura, S., Vatner, D. E., Kurotani, R., Bai, Y., Gao, S., Yuan, Z., et al. (2007). Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress. Circulation, 116(16), 1776–1783. https://doi.org/10.1161/CIRCULATIONAHA.107.701169

Osimo, E. F., Pillinger, T., Rodriguez, I. M., Khandaker, G. M., Pariante, C. M., & Howes, O. D. (2020). Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun, 87, 901–909. https://doi.org/10.1016/j.bbi.2020.02.010

Park, C., Rosenblat, J. D., Brietzke, E., Pan, Z., Lee, Y., Cao, B., et al. (2019). Stress, epigenetics and depression: a systematic review. Neurosci Biobehav Rev, 102, 139–152. https://doi.org/10.1016/j.neubiorev.2019.04.010

Pittenger, C., & Duman, R. S. (2008). Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology, 33(1), 88–109. https://doi.org/10.1038/sj.npp.1301574

Ruisoto, P., & Contador, I. (2019). The role of stress in drug addiction: an integrative review. Physiol Behav, 202, 62–68. https://doi.org/10.1016/j.physbeh.2019.01.022

Shah, R. R., & Smith, R. L. (2015). Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos, 43(3), 400–410. https://doi.org/10.1124/dmd.114.061093

Siopi, E., Chevalier, G., Katsimpardi, L., Saha, S., Bigot, M., Moigneu, C., et al. (2020). Changes in gut microbiota by chronic stress impair the efficacy of fluoxetine. Cell Rep, 30(11), 3682–3690.e6. https://doi.org/10.1016/j.celrep.2020.02.099

Stalder, T., Steudte-Schmiedgen, S., Alexander, N., Klucken, T., Vater, A., Wichmann, S., et al. (2017). Stress-related and basic determinants of hair cortisol in humans: a meta-analysis. Psychoneuroendocrinology, 77, 261–274. https://doi.org/10.1016/j.psyneuen.2016.12.017

Vanuytsel, T., van Wanrooy, S., Vanheel, H., Vanormelingen, C., Verschueren, S., Houben, E., et al. (2014). Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut, 63(8), 1293–1299. https://doi.org/10.1136/gutjnl-2013-305690

Vrijens, B., De Geest, S., Hughes, D. A., Przemyslaw, K., Demonceau, J., Ruppar, T., et al. (2012). A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol, 73(5), 691–705. https://doi.org/10.1111/j.1365-2125.2012.04167.x

Webster Marketon, J. I., & Glaser, R. (2008). Stress hormones and immune function. Cell Immunol, 252(1–2), 16–26. https://doi.org/10.1016/j.cellimm.2007.09.006

Wild, C. P. (2012). The exposome: from concept to utility. Int J Epidemiol, 41(1), 24–32. https://doi.org/10.1093/ije/dyr236

Yuan, M., Yang, B., Rothschild, G., Mann, J. J., Sanford, L. D., Tang, X., et al. (2023). Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential. Signal Transduct Target Ther, 8(1), 309. https://doi.org/10.1038/s41392-023-01528-9

Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther, 138(1), 103–141. https://doi.org/10.1016/j.pharmthera.2012.12.007

Zannas, A. S., Wiechmann, T., Gassen, N. C., & Binder, E. B. (2016). Gene–stress–epigenetic regulation of FKBP5: clinical and translational implications. Neuropsychopharmacology, 41(1), 261–274. https://doi.org/10.1038/npp.2015.235

Zemanová, N., Anzenbacher, P., Zapletalová, I., Jourová, L., Hermanová, P., Hudcovic, T., et al. (2020). The role of the microbiome and psychosocial stress in the expression and activity of drug-metabolizing enzymes in mice. Sci Rep, 10(1), 8529. https://doi.org/10.1038/s41598-020-65391-7

Zheng, G., Wu, S. P., Hu, Y., Smith, D. E., Wiley, J. W., & Hong, S. (2013). Corticosterone mediates stress-related increased intestinal permeability in a region-specific manner. Neurogastroenterol Motil, 25(2), e127–39. https://doi.org/10.1111/nmo.12066

Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019). Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature, 570(7762), 462–467. https://doi.org/10.1038/s41586-019-1291-3

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.